How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

429 results for

Corticotropin Stimulation Test

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders

(as needed based on patient’s presenting symptoms) Basic lab tests ? Complete blood count ? Fasting glucose ? Fasting lipid profile (TC, vLDL, LDL, HDL, TG) ? Thyroid-stimulating hormone ? Electrolytes ? Liver enzymes If warranted ? Urine toxicology for substance use Adapted from references [32,53]. HDL = high density lipoprotein; LDL = low density lipoprotein; TC = total cholesterol; TG = triglyceride; vLDL = very low density lipoprotein. Katzman et al. BMC Psychiatry 2014, 14(Suppl 1):S1 http (...) of the anxiety symptoms, associations with life events or trauma, the nature of the anxiety (i.e., worry, avoidance, or obsession), and the impact they have had on the patient’s current functioning. Table 5 presents suggested screening questions for individual anxiety and related disorders, from various validated screening tools [27-30], some of which are freely available online (e.g., http://www.macanxiety.com/ online-anxiety-screening-test). Conduct differential diagnosis The differential diagnosis

2014 CPG Infobase

42. Neofordex - dexamethasone. To treat adults with multiple myeloma

II, or give the monohydrate. Form I, the more stable form, can only be generated from Form II at high temperature, but not from the hydrated forms. Intrinsic Dissolution Rates (IDR) of the different polymorphs were studied. The morphology of the active substance produced by the active ingredient manufacturer is determined and controlled by an XRPD method with a test and control limits included within the specification for the active substance. Specification The control tests comply (...) with the specification and test methods of the Ph. Eur. Monograph for dexamethasone acetate and additional test mentioned in the CEP. Additional specifications have also been set for particle size (laser diffraction) and polymorphism (XRPD). All additional methods have been adequately validated and described according to ICH Q2. Control limits for particle size distribution and morphology are justified in view of the characteristics of the batch of active substance used for the bioequivalence study. Batch analysis

2016 European Medicines Agency - EPARs

43. Guideline on the management of premature ovarian insufficiency

) antibodies should be performed in women with POI of unknown cause or if an immune disorder is suspected. In patients with a positive TPO-Ab test, thyroid stimulating hormone (TSH) should be measured every year. C 10 There is insufficient evidence to recommend routinely screening POI women for diabetes. D There is no indication for infection screening in women with POI. D The possibility of POI being a consequence of a medical or surgical intervention should be discussed with women as part (...) for at least 4 months, and ? an elevated FSH level > 25 IU/l on two occasions > 4 weeks apart. GPP What are the known causes of POI and how should they be investigated? Chromosomal analysis should be performed in all women with non-iatrogenic Premature Ovarian Insufficiency. C Gonadectomy should be recommended for all women with detectable Y chromosomal material. C Fragile-X premutation testing is indicated in POI women. B The implications of the fragile-X premutation should be discussed before the test

2015 European Society of Human Reproduction and Embryology

44. Alcohol-induced Cushing syndrome. Hypercortisolism caused by alcohol abuse. (PubMed)

. Studies using corticotropin-releasing hormone stimulation and tests after ethanol ingestion revealed inconclusive results.There is no clear definition for the alcohol-induced pseudo-Cushing state, and hitherto studies fail to provide clues to differentiate between pseudo-Cushing and Cushing's syndrome. Only cessation of alcohol can normalise biochemical abnormalities and regress hypercortisolic symptoms. (...) the severity of the changes varied widely. The most frequently occurring abnormalities were: insufficient suppression after low-dose dexamethasone or increased 24-hour urinary free cortisol (UFC). After alcohol withdrawal, cortisol decreased and dexamethasone-induced suppression of cortisol increased. No differences were noted between alcoholic and control subjects after an ACTH stimulation test, insulin tolerance test or metyrapone test. Differences were found after a naloxone test and hexarelin test

2020 Netherlands Journal of Medicine

45. Adjustment to Cancer: Anxiety and Distress (PDQ®): Health Professional Version

is adjusting.[ ] Self-Report Screening Instruments Studies have tested the ability of single-item measures to accurately identify patients in distress.[ - ] In general, these ultrashort screening methods, such as the Distress Thermometer (DT), have demonstrated only modest overall accuracy. They are best for ruling out—but performed poorly at confirming—distress, anxiety, and depression. The Distress Thermometer (DT) The DT, the National Comprehensive Cancer Network (NCCN) single-item and rapid-screening (...) instrument, asks patients to rate their distress on a scale of 0 to 10, with 10 being extreme distress. On an accompanying problem checklist, patients are asked to indicate what has been a problem for them in the past week.[ ] Although many screening instruments have been tested with cancer patients, the DT has been the most widely investigated. The psychometric properties of the DT—a 0-to-10 visual analog scale in the form of a thermometer labeled No distress at 0 and Extreme distress at 10—have been

2018 PDQ - NCI's Comprehensive Cancer Database

46. Late Effects of Treatment for Childhood Cancer (PDQ®): Health Professional Version

of cardiac, pulmonary, and metabolic late effects.[ - ] Access to risk-based survivor care Most childhood cancer survivors do not receive recommended risk-based care. The CCSS observed the following: 88.8% of survivors reported receiving some form of medical care.[ ] 31.5% reported receiving care that focused on their previous cancer (survivor-focused care).[ ] 17.8% reported receiving survivor-focused care that included advice about risk reduction and discussion or ordering of screening tests (...) .[ - ] Treatment of childhood HL with higher cumulative doses of alkylating agents and ovarian radiation of 5 Gy or higher (exposures predisposing to premature menopause) have been correlated with reductions in breast cancer risk, underscoring the potential contribution of hormonal stimulation on breast carcinogenesis.[ , , ] Most data describing the risk of radiation-associated breast cancer are based on patients treated for HL, with doses ranging from 15 Gy to 50 Gy. However, the risk of breast cancer

2018 PDQ - NCI's Comprehensive Cancer Database

47. Hormonal Replacement in Hypopituitarism in Adults

to diagnose AI. (1|⊕⊕⚪⚪) 1.3 We suggest that a cortisol level <3 μg/dL is indicative of AI and a cortisol level >15 μg/dL likely excludes an AI diagnosis. (2|⊕⚪⚪⚪) 1.4 We suggest performing a corticotropin stimulation test when morning cortisol values are between 3 and 15 μg/dL to diagnose AI. Peak cortisol levels <18.1 μg/dL (500 nmol/L) at 30 or 60 minutes indicate AI. (2|⊕⊕⚪⚪) 1.5 We suggest that clinicians perform biochemical testing for the hypothalamic-pituitary-adrenal (HPA) axis at least 18–24 (...) to evaluate central hypothyroidism, a condition where the thyroid gland does not produce enough hormones because it isn’t stimulated by the pituitary gland. People who have central hypothyroidism should be treated with levothyroxine in doses sufficient to raise levels of the thyroid hormone free thyroxine to the upper half of the reference range. Growth hormone stimulation testing should be used to diagnose patients with suspected growth hormone deficiency. People who have proven cases of growth hormone

2016 The Endocrine Society

48. Diagnosis and Treatment of Primary Adrenal Insufficiency

| ENDO 2017 Essential Points The Endocrine Society recommends that acutely ill patients who have unexplained symptoms undergo diagnostic testing to rule out primary adrenal insufficiency. Those who have severe symptoms of the condition or adrenal crisis should undergo immediate treatment with medication until diagnostic test results are available. Health care providers should conduct a corticotropin stimulation test to confirm the diagnosis when the patient’s condition allows. Patients should undergo (...) corticotropin stimulation (30 or 60 min) test over other existing diagnostics tests to establish the diagnosis of adrenal insufficiency. Peak cortisol levels below 500 nmol/L (18 μg/dL) (assay dependent) at 30 or 60 minutes indicate adrenal insufficiency. (2|⊕⊕⚪⚪) 2.2 We suggest the low-dose (1 μg) corticotropin test for diagnosis of PAI only when the substance itself is in short supply. (2|⊕⊕⚪⚪) 2.3 If a corticotropin stimulation test is not feasible, we suggest using a morning cortisol <140 nmol/L (5 μg

2016 The Endocrine Society

49. Revised ATA guidelines for the management of medullary thyroid carcinoma

to the neck 52 591–592 [T] Evaluation of patients with distant metastases 592 [T-1] Role of open or laparoscopic evaluation of the liver and selective venous catheterization with measurement of hepatic and peripheral vein stimulated Ctn levels 53, 54 592 [U] Diagnosis and treatment of patients with clinically evident metastatic disease 592 [U-1] Brain metastases 55 592–593 [U-2] Bone metastases 56–58 593 [U-3] Lung and mediastinal metastases 59 593 [U-4] Hepatic metastases 60 593 [U-5] Cutaneous (...) Carcinoembryonic antigen CLA Cutaneous lichen amyloidosis CRH Corticotropin-releasing hormone CT Computed tomography (tomographic) Ctn Calcitonin EBRT a External beam radiation therapy EMA European Medicines Agency FDA U.S. Food and Drug Administration FDG-PET 2-[Fluorine-18]?uoro-2-deoxy-D-glucose- positron emission tomography F-DOPA 18 F-dihydroxyphenylalanine FMTC Familial medullary thyroid cancer FNA Fine-needle aspiration FTC Follicular thyroid carcinoma HD Hirschsprung’s disease HIPAA Health Insurance

2015 Pediatric Endocrine Society

50. Enhanced Recovery After Surgery (ERAS) for gastrointestinal surgery, part 1: pathophysiological considerations

recovery adversely. Reducing neuro‐humoral stimulation may be achieved by reducing access trauma and internal trauma associated with the surgery. Trauma to the abdominal wall may be reduced by changing the orientation of the incision such that it traverses fewer myotomes and dermatomes. Where open surgery is performed, transverse incisions may reduce post‐operative pain and improve outcomes but the evidence for this is not clear. - The length of the access incision can be reduced using laparoscopic (...) the necessity to dissect carefully within bloodless plains where possible which may have a benefit in reducing collateral injury and reducing stimulation. This results in a reduction in secondary injury reducing the cytokine, hormonal and neural responses to surgery. The benefits of MIS are further enhanced by reducing consequential problems from fasting and immobilisation as there is a more rapid return of gut function and improved mobilisation. The benefits from using MIS has to be balanced against

2015 ERAS Society

51. Ketoconazole HRA

2.8. Risk Management Plan 79 2.9. Product information 84 3. Benefit-Risk Balance 85 Benefits 85 Risks 86 Benefit-risk balance 88 4. Recommendations 89 Ketoconazole HRA Assessment report EMA/CHMP/534845/2014 Page 3/115 List of abbreviations ACTH Adrenocorticotrophin Hormone AE Adverse events AGT Aminoglutethimide AI Adrenal insufficiency ALT Alanine transaminase AP Alkaline phosphatase AST Aspartate transaminase AUC Area under the curve b.i.d Twice a day CD Cushing’s disease CRH Corticotropin (...) applied for the following indication: Treatment of Cushing’s syndrome. The legal basis for this application refers to: Article 10(a) of Directive 2001/83/EC – relating to applications relying on well-established medicinal use supported by bibliographic literature. The application submitted is composed of administrative information, complete quality data, non-clinical and clinical data based on bibliographic literature substituting all non-clinical tests and clinical studies together

2014 European Medicines Agency - EPARs

52. Late Effects of Treatment for Childhood Cancer (PDQ®): Health Professional Version

of cardiac, pulmonary, and metabolic late effects.[ - ] Access to risk-based survivor care Most childhood cancer survivors do not receive recommended risk-based care. The CCSS observed the following: 88.8% of survivors reported receiving some form of medical care.[ ] 31.5% reported receiving care that focused on their previous cancer (survivor-focused care).[ ] 17.8% reported receiving survivor-focused care that included advice about risk reduction and discussion or ordering of screening tests (...) .[ - ] Treatment of childhood HL with higher cumulative doses of alkylating agents and ovarian radiation of 5 Gy or higher (exposures predisposing to premature menopause) have been correlated with reductions in breast cancer risk, underscoring the potential contribution of hormonal stimulation on breast carcinogenesis.[ , , ] Most data describing the risk of radiation-associated breast cancer are based on patients treated for HL, with doses ranging from 15 Gy to 50 Gy. However, the risk of breast cancer

2016 PDQ - NCI's Comprehensive Cancer Database

53. Signifor - pasireotide

Risks 86 Benefit-risk balance 88 4. Recommendations 89 Outcome 89 Page 3/90 Conditions or restrictions regarding supply and use 89 Conditions and requirements of the Marketing Authorisation 89 New Active Substance Status 90 Page 4/90 List of abbreviations ACTH Adrenocorticotropic hormone AE Adverse Event b.i.d. bis in die/twice a day BMI Body mass index CI Confidence interval CRH Corticotropin-releasing hormone HRQL Health related quality of life IPSS Inferior petrosal sinus sampling ITT Intent (...) of Cushing’s disease. The applicant applied for the following indication: “Treatment of adult patients with Cushing’s disease for whom surgery is not an option or for whom surgery has failed.” The legal basis for this application refers to: Article 8.3 of Directive 2001/83/EC - complete and independent application. The application submitted is composed of administrative information, complete quality data, non- clinical and clinical data based on applicants’ own tests and studies and/or bibliographic

2012 European Medicines Agency - EPARs

54. Sex differences in the ACTH and cortisol response to pharmacological probes are stressor-specific and occur regardless of alcohol dependence history. (PubMed)

and may involve both central and peripheral mechanisms regulating the limbic-hypothalamic-pituitary-adrenal axis. In the present randomized, double blind, placebo-controlled, triple-dummy crossover study, we juxtaposed a centrally-acting, citalopram (2 mg/unit BMI) neuroendocrine stimulation test with a peripherally-acting, dexamethasone (Dex) (1.5 mg)/corticotropin-releasing factor (CRF) (1 μg/kg) test in euthymic women (N = 38) and men (N = 44) with (54%) and without histories of alcohol dependence (...) /CRF test than they did the citalopram test while men exhibited the opposite pattern of results. Women also had more robust ACTH, cortisol and body temperature responses to Dex/CRF than men, and exhibited a shift in their adrenal glands' sensitivity to ACTH as measured by the cortisol/log (ACTH) ratio during that session in contrast to the other test days. Our findings indicate that central serotonergic and peripheral mechanisms both play roles in mediating sexually dimorphic, stressor-specific

Full Text available with Trip Pro

2018 Psychoneuroendocrinology Controlled trial quality: uncertain

55. Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

and >3 after corticotropin-releasing hormone (CRH) stimulation Recurrent or persistent Cushing disease defined as pathologically confirmed resected pituitary ACTH-secreting tumor, and 24 hour UFC above the upper limit of normal reference range beyond post-surgical week 6 Patients on medical treatment for Cushing disease. Washout periods must be completed before screening assessments are performed. Exclusion criteria: Patients with compromised visual fields, and not stable for at least 6 months (...) or the evaluation of its results, such as History of immunocompromise, including a positive HIV test result (ELISA and Western blot). An HIV test will not be required, however, previous medical history will be reviewed Presence of active or suspected acute or chronic uncontrolled infection History of, or current alcohol misuse/abuse in the 12 month period prior to screening Female patients who are pregnant or lactating, or are of childbearing potential and not practicing a medically acceptable method of birth

2018 Clinical Trials

56. Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer

anticoagulant therapy. For patients on anticoagulant therapy, PT/INR must be within therapeutic range. Activated partial thromboplastin time (aPTT) =< 1.5 x ULN unless subject is receiving anticoagulant therapy. For patients on anticoagulant therapy, PT/INR must be within therapeutic range Thyroid-stimulating hormone (TSH), thyroxine (T4) and corticotropin (ACTH) within normal range (prior to registration). Proteinuria within institutional normal or =< grade 1 OR urinary protein < 1 g/24 hours (hr) (prior (...) markers [ Time Frame: Up to 2 years ] Will be assessed for change using paired statistical methods such as paired t-tests or signed rank tests. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below

2018 Clinical Trials

57. Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR)

. It stimulates the adrenal cortex to produce and secrete glucocorticoids. ACTH is available for clinical usage as an injectable gel (H.P. Acthar®). Other Names: H.P. Acthar Gel Repository Corticotropin Injection Outcome Measures Go to Primary Outcome Measures : Change in mean aqueous levels of albumin in post-operative PVR patients receiving subcutaneous injections of H.P. Acthar® [ Time Frame: Baseline, 1 day after surgery, 1 week after surgery, 8 weeks after surgery ] The levels of albumin in the aqueous (...) , with higher scores corresponding to better visual acuity (a score of 100 corresponding to a Snellen visual acuity of 20/10). Percentage of post-operative PVR patients receiving subcutaneous injections of H.P. Acthar® who develop recurrent retinal detachment [ Time Frame: 12 weeks after surgery ] Recurrent retinal detachment is a common complication of PVR. It will be diagnosed based on clinical exam and supporting information from diagnostic tests such as Optical Coherence Tomography. Percentage of post

2018 Clinical Trials

58. Clinical Trial to Investigate CT38 in the Treatment of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome

Identifier: NCT03613129 Recruitment Status : Recruiting First Posted : August 2, 2018 Last Update Posted : August 2, 2018 See Sponsor: LUCINDA BATEMAN, MD Information provided by (Responsible Party): LUCINDA BATEMAN, MD, Bateman Horne Center Study Details Study Description Go to Brief Summary: This study seeks to examine the effect of a subcutaneous infusion of CT38, an experimental peptide, on cardio-pulmonary exercise test (CPET) performance and CPET-induced changes in functional capacity and symptom (...) levels (assessed by, Fitbit monitoring, DANA cognitive testing and patient-reported outcome measures) in ME/CFS. Condition or disease Intervention/treatment Phase Myalgic Encephalomyelitis Chronic Fatigue Syndrome Drug: CT38 Phase 1 Phase 2 Detailed Description: Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) is a complex disorder that may be triggered by infection or other stressors (e.g., emotional or physical trauma, immune activation, chemical exposures). Its hallmark is a reduced

2018 Clinical Trials

59. Spontaneous adrenocorticotropic hormone (ACTH) normalisation due to tumour regression induced by metyrapone in a patient with ectopic ACTH syndrome: case report and literature review. (PubMed)

lung. There was no adrenal gland enlargement. Tumour markers were not significantly elevated; ACTH levels were not suppressed by 8-mg dexamethasone. A corticotropin-releasing hormone stimulation test revealed blunted ACTH response (basal ACTH, 204.6 pg/mL; highest ACTH level during the 120-min stimulation test, 214.0 pg/mL). She was diagnosed with EAS due to a lung lesion. MTP treatment was started to reduce cortisol production. ACTH levels and cortisol and UFC levels were normalised and the ACTH

Full Text available with Trip Pro

2018 BMC Endocrine Disorders

60. Secondary adrenal insufficiency and pituitary dysfunction in oral/transdermal opioid users with non-cancer pain (PubMed)

collected prior to 0900 h. Further testing with corticotropin (250 µg IV) and metyrapone (30 mg/kg) stimulation tests was undertaken on participants with serum cortisol <250 nmol/L. Validated questionnaires completed to assess QoL, fatigue and sexual function. Results Secondary adrenal insufficiency (SAI) was identified on the basis of a failed stimulation test in 22.5% of opioid users vs no controls (P = 0.01). Opioid users with SAI had a higher median morphine-equivalent daily dose (MEDD), P = 0.037

Full Text available with Trip Pro

2018 European Journal of Endocrinology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>